SCHEMBL359139

SCHEMBL359139

Cn1cc(-n2ccc(=O)c(COc3ccc4ncc(NC(=O)O)cc4c3)n2)cn1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MET P08581 9/20 0.36
MAPK1 P28482 3/20 0.36
AURKB Q96GD4 3/20 0.36
SIRT2 Q8IXJ6 2/20 0.35
PDE10A Q9Y233 1/20 0.35
MAOB P27338 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
JAK3 P52333 1/20 0.33
NTRK1 P04629 1/20 0.33
YES1 P07947 1/20 0.33
PIM1 P11309 1/20 0.33
NOTUM Q6P988 1/20 0.33
MCHR1 Q99705 1/20 0.33
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
FGFR4 P22455 1/20 0.33
FGFR3 P22607 1/20 0.33
KDR P35968 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10283540 0.94 AURKB (0.40) METMAPK1AURKBSIRT2PDE10A
SCHEMBL14926940 0.90 GSK3B (0.39) METMAPK1AURKBSIRT2NTRK1
SCHEMBL14916951 0.88 MET (0.41) METPDE10AMAOBFGFR1FGFR2
SCHEMBL14916275 0.87 MET (0.41) METPDE10AFGFR1FGFR2FGFR4
SCHEMBL360598 0.87 PDE10A (0.38) METPDE10AFGFR1FGFR3
SCHEMBL255618 0.87 PDE10A (0.38) METPDE10AFGFR1FGFR2FGFR4
SCHEMBL12503425 0.86 MEN1 (0.40) SIRT2MCHR1
Hydrochloric Acid SCHEMBL174468 0.86 PDE10A (0.37) METPDE10AFGFR1FGFR2FGFR4
SCHEMBL368325 0.85 MET (0.43) METPDE10AMAOBFGFR1FGFR2
SCHEMBL358857 0.85 MET (0.38) METPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP claimed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US claimed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO claimed
EP-2593107-A1 TYROSINE KINASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-05-22 EP disclosed
US-20130116231-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. 2013-05-09 US disclosed
WO-2012009194-A1 TYROSINE KINASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116231-A1 TYROSINE KINASE INHIBITORS ABL1, ERBB2, MET MET 3/4885MAPK1 390/4885AURKB 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.